Leaders in Pharmaceutical Business Intelligence (LPBI) Group

2017 Raising Star: Dr. Dean Y. Li, MD, PhD – VP, Head Translational Medicine, Merck

Editor-in-Chief http://pharmaceuticalintelligence.com: Aviva Lev-Ari, PhD, RN

 

On May 1-3, 2017 –  I covered for the Press in Real Time the following event. The e-Reader is encouraged to click on each of the three links below.

 

• World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

(a) Real Time Highlights and Tweets: Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

• https://pharmaceuticalintelligence.com/2017/05/03/deliverables-day-123-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma-httpsworldmedicalinnovation-orgagenda-highlights-of-live-day-1-world-medical/

(b) e-Proceedings for Day 1,2,3: World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

• https://pharmaceuticalintelligence.com/2017/05/05/e-proceedings-for-day-123-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma/

(c)  Tweets by @pharma_BI and @AVIVA1950 at World Medical Innovation Forum – CARDIOVASCULAR • MAY 1-3, 2017, BOSTON, MA

• https://pharmaceuticalintelligence.com/2017/05/05/tweets-by-pharma_bi-and-aviva1950-at-world-medical-innovation-forum-cardiovascular-%E2%80%A2-may-1-3-2017-boston-ma/

From this event, I plan to write about the 

Disruptive Dozen: 12 Technologies that will reinvent Cardiovascular Care

Moderator: Calum MacRae, MD, PhD

• Chief of Cardiovascular Medicine, Brigham and Women’s Hospital
• Associate Professor of Medicine, Harvard Medical School

Anthony Rosenzweig, MD

• Chief, Cardiology Division, Massachusetts General Hospital
• Professor of Medicine, Harvard Medical School

12. Aging and Heart Disease: Can we reverse the process?

11.Nanotechnologies for Cardiac Diagnosis and Treatment

10. Breaking the Code: Diagnosis and Therapeutic Potential of RNA

9. Expanding the Pool of Organs for Transplant

8. Finding Cancer therapies without Cardiotoxicity

7. Less is more: Minimalist Mitral Valve Repair

6. Understanding Why exercise works for Just about every thing

5. Power Play: The Future of Implantable Cardiac Devices

4. Adopting the Orphan of Heart Disease

3. Targeting Inflammation in cardiovascular Disease

2. Harnessing Big Data and Deep Learning for Clinical Decision Support

1. Quantitative Molecular Imaging for Cardiovascular Phynotypes

 

Here, I wish to present the PROFILE of my own selection for the 2017 Raising Star: Dr. Dean Y. Li, MD, PhD  VP, Head Translational Medicine, Merck. His comments were per my judgement, among the most insightful.

 

Dr. Dean Y. Li, MD, PhD  VP, Head Translational Medicine, Merck

His lab has developed mouse models for three human vascular diseases:

• supravalvular stenosis,
• hereditary hemorrhagic telangiectasia,
• cerebral cavernous malformations

Co-Founder of Early stage Biotech start ups:

• Hydra Bioscience,
• Navigen
• Recursion Pharmaceuticals

Education

• University of Chicago, BSc
• Washington University in St. Louis, MD/PhD
• University of Utah, 1994 as a Postdoctoral Fellow in Cardiology

 

• 2016 – Vice Dean for Research for the School of Medicine and Associate Vice President for Research & Chief Scientific Officer, Health Sciences

  University of Utah School of Medicine

• 

  

• Co Founder & CSO

  Salt Lake City, UT

Dr. Dean Y. Li, MD, PhD

5/2017 – VP, Head Translational Medicine, Merck

Past

Dr. Dean Y. Li is the H.A., and Edna Benning Endowed Professor of Internal Medicine and Director of the University of Utah Molecular Medicine (U2M2) Program and the MD/PhD Program. He received his Bachelor’s degree from the University of Chicago and his MD/PhD from Washington University in St. Louis. He began his career at the University of Utah in 1994 as a Postdoctoral Fellow in Cardiology. He received his first faculty appointment in 1996 which launched his career at the University of Utah. As is Associate Vice President for Research and Chief Scientific Officer for University of Utah Health Sciences, and Vice Dean for Research for the School of Medicine. Dr. Li is responsible for oversight of the research enterprise in the health sciences, including development and realization of a strategic plan for research. As Chief Scientific Officer, he is responsible for coordinating and maximizing the University’s health system investment in translational, clinical, and health care research leading to new treatments and health system innovations for patients.

Dr. Li is the recipient of multiple honors including the Established Investigator Award by the American Heart Association and Clinical Scientist Award in Translation Medicine from the Burroughs Wellcome Foundation and recently in May of 2014, he is the recipient of the Mark Brothers Award from Indiana University. In 2009 he received a Clinical Faculty Teaching Award and in 2010 he was inducted to the American Association of Physicians.

Dr. Li is a distinguished scientist and is internationally recognized for his groundbreaking research in vascular development and disease. His lab has developed mouse models for three human vascular diseases: supravalvular stenosis, hereditary hemorrhagic telangiectasia, and cerebral cavernous malformations. Through studying these diseases, he has identified a blood vessel protein that reversed or prevented age-related macular degeneration and diabetic retinopathy in mouse models. He also identified a family of proteins that accelerated blood vessel growth in ischemic mice and restored blood vessel growth in diabetic mice. Those discoveries have opened the door to developing drug therapies to treat those diseases.

Dr. Li has served as a reviewer for the AHA and for several study sections of the NIH. He is a member of the American Society of Clinical Investigators. He is the author of multiple manuscripts published in peer reviewed journals including Science and Nature. He is a current member of the AHA and NAVBO, co-founder of Hydra Bioscience, Navigen and Recursion Pharmaceuticals. His broad experiences and expertise in bench science, clinical medicine and biotechnology, combined with his success as a leader and mentor enable him to have a major impact on the School of Medicine’s mission to advance science and translate discoveries into clinical applications and better health care for patients.

SOURCE

http://www.u2m2.utah.edu/director/